AlloVir, Inc. (NASDAQ:ALVR) CEO Sells $174,929.80 in Stock

AlloVir, Inc. (NASDAQ:ALVRGet Rating) CEO Diana Brainard sold 34,435 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $5.08, for a total transaction of $174,929.80. Following the completion of the transaction, the chief executive officer now directly owns 601,607 shares of the company’s stock, valued at approximately $3,056,163.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Diana Brainard also recently made the following trade(s):

  • On Friday, November 18th, Diana Brainard sold 4,515 shares of AlloVir stock. The shares were sold at an average price of $7.27, for a total transaction of $32,824.05.

AlloVir Stock Performance

Shares of ALVR stock opened at $5.43 on Wednesday. AlloVir, Inc. has a one year low of $3.17 and a one year high of $10.29. The company has a 50 day moving average price of $6.18 and a 200 day moving average price of $6.95. The firm has a market capitalization of $505.88 million, a price-to-earnings ratio of -1.94 and a beta of 0.87.

AlloVir (NASDAQ:ALVRGet Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.02. As a group, equities analysts forecast that AlloVir, Inc. will post -2.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, SVB Leerink dropped their price target on shares of AlloVir from $25.00 to $19.00 and set an “outperform” rating for the company in a research report on Monday.

Institutional Investors Weigh In On AlloVir

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in AlloVir by 42.1% during the third quarter. Vanguard Group Inc. now owns 2,911,200 shares of the company’s stock worth $22,969,000 after buying an additional 863,190 shares during the period. BlackRock Inc. grew its stake in AlloVir by 7.6% during the third quarter. BlackRock Inc. now owns 2,667,480 shares of the company’s stock worth $21,047,000 after buying an additional 188,875 shares during the period. GMT Capital Corp grew its stake in AlloVir by 66.2% during the second quarter. GMT Capital Corp now owns 1,891,170 shares of the company’s stock worth $7,376,000 after buying an additional 753,100 shares during the period. State Street Corp boosted its stake in shares of AlloVir by 21.8% in the third quarter. State Street Corp now owns 877,501 shares of the company’s stock valued at $6,923,000 after purchasing an additional 157,300 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of AlloVir by 7.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 835,779 shares of the company’s stock valued at $6,594,000 after purchasing an additional 56,611 shares during the period.

AlloVir Company Profile

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Featured Articles

Insider Buying and Selling by Quarter for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.